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 Pain is a common symptom in many types of cancer. 
 Interdisciplinary team management, including pain 
 assessment, explanation to the patient/family, treating the 
reversible, non-pharmacological treatments and reassessment 
are essential. This article focuses on the pharmacological 
 management of cancer pain, and overviews and updates on 
the recent advances in this fi eld. Both non-opioid and opioid 
analgesia as well as  coanalgesics (adjuvants) are reviewed. 
Within non-opioid analgesia the risks of non-steroidal anti-
infl ammatory drugs (NSAIDs) are considered and recom-
mendations for NSAIDs in patients at risk of gastrointestinal 
and cardiovascular  toxicity are made. For opioid analgesics, 
side effects of opioids are  discussed alongside practical guid-
ance on opioid prescribing and converting between opioids. 
Newer drugs such as  tapentadol are considered in this update. 
Amitriptyline,  duloxetine, gabapentin and pregabalin, and 
the guidance for their use are reviewed in the coanalgesics 
(adjuvants) section. 
 KEYWORDS :  Pain, neoplasms, analgesics, opioid, tapentadol, non-
steroidal anti-infl ammatory agents 
 Background 
 Patients receiving palliative care can have many different 
symptoms, including pain. An update on drugs for other symptoms 
is reviewed separately in this issue. 1 Pain is a common symptom in 
many advanced illnesses. However, it is often poorly managed. 2 
Initial pain assessment (with the aim of finding a cause, assessing 
reversibility and the impact on the patient and their family, and 
to formulate a management plan), followed by reassessment of 
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to the patient/family, treating the reversible where appropriate 
and non-pharmacological treatments (often delivered by an 
interdisciplinary team) are essential, but outside the scope of 
the article. This review article will highlight recent updates in the 
pharmacological management of cancer pain in patients receiving 
palliative care. 
 Traditionally, the three-step World Health Organization (WHO) 
analgesic ladder has guided the pharmacological treatment of 
cancer pain. 3 Although there is some evidence supporting the use 
of WHO recommendations in treating cancer pain, there is a lack 
of randomised controlled trial (RCT) data. 4 Nonetheless, opioids 
such as codeine, morphine, oxycodone and fentanyl are often used 
in conjunction with paracetamol +/- NSAIDs and coanalgesics 
(adjuvants) to manage cancer pain. Other treatment modalities 
outside the WHO analgesic ladder (including interventional 
techniques like nerve blocks or intrathecal analgesia delivery) are 
also endorsed in the original WHO recommendations. 4 In order 
to gain maximum benefit from these therapeutic options, they 
should be considered alongside the WHO analgesic ladder for 
patients likely to require them, rather than as a final step. 4 
 Non-opioid analgesics 
 Paracetamol 
 A recent Cochrane review assessed the role of oral paracetamol in 
the management of cancer pain. 5 There were three small RCT’s 
included. All three studies assessed paracetamol in combination 
with opioids; there was high risk of bias. None assessed the use of 
paracetamol alone (first step). Overall, there was no high-quality 
evidence for or against using paracetamol (alone or with opioids) 
for cancer pain. 5 
 Non-steroidal anti-infl ammatory drugs 
 Non-steroidal anti-inflammatory drugs are used in palliative care 
for pain related to inflammation, which is an underlying aetiology 
in many people with cancer pain. 2 The role of NSAIDs in cancer 
pain was assessed in a recent Cochrane review. 6 Nine of the 11 
included studies had substantial risk of bias, being small and having 
incomplete outcome data. In four studies, NSAIDS initially reduced 
moderate or severe pain after 1 or 2 weeks (415 participants). 
Overall, there was no high-quality evidence for or against the use of 
NSAIDs (alone or with opioids). 
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 Studies examining NSAID use in other conditions can provide 
baseline safety information, with the understanding that cancer 
and other serious illness carry additional NSAID toxicity risks. 
Non-steroidal anti-inflammatory drugs can have gastrointestinal 
(GI), renal and cardiovascular (CV) toxicity. 2,7,8 A meta-analysis 
of RCTs, 7 for all types of pain identified that COX-2 selective 
inhibitors (coxibs) increased major vascular events by a third 
compared to placebo (rate ratio 1.37, 95% confidence interval 
[CI] 1.14–1.66, p=0.0009), mainly due to major coronary events. 
The vascular risk of different coxibs were similar. The risk of 
vascular death was significantly increased by coxibs (1.58, 95% 
CI 1.00–2.49, p=0.0103) and diclofenac (1.65, 95% CI 0.95–2.85, 
p=0.0187), increased by ibuprofen (1.90, 95% CI 0.56–6.41, 
p=0.17), but not increased by naproxen (1.08, 95% CI 0.48–
2.47, p=0.80). 
 The risk of upper GI complications, compared with placebo, was 
doubled with coxibs and diclofenac, and quadrupled with high doses 
of ibuprofen (2400 mg/24 hr) and naproxen (1000 mg/24 hr). Only 
2% of upper GI complications were fatal. Heart failure risk leading 
to hospital admission was doubled by all NSAIDs. 7 Celecoxib and 
diclofenac have a lower risk of upper GI complications but higher risk 
of major CV events. They should be avoided in patients with CV risk 
factors. 
 Patients with rheumatoid arthritis or osteoarthritis and increased 
CV risk were randomly assigned to receive celecoxib (100 mg twice 
a day), ibuprofen (600 mg three times a day) or naproxen (375 
mg twice a day) with matching placebo. 8 Cardiovascular death 
was not higher with moderate doses of celecoxib compared with 
nonselective NSAIDs (hazard ratio [HR] for celecoxib vs naproxen: 
0.93, 95% CI 0.76–1.130; HR for celecoxib vs ibuprofen: 0.85, 95% 
CI 0.70–1.04, p<0.001). 8 
 Based on individual risk of GI or CV toxicity, the following 
recommendations are made about NSAID choice: 7 , 9–11 
 >  no CV or GI risk: non-selective NSAID (eg naproxen, ibuprofen, 
diclofenac) 
 >  GI risk and no CV risk: avoid if possible; if essential celecoxib* 
(200 mg/24 h) 
>  CV risk +/- GI risk: avoid if possible; naproxen (1 g/24 h) or low 
dose ibuprofen (<1200 mg/24 h). 
 *Note: celecoxib use in patients with CV and GI risks is 
contraindicated by the manufacturer. 
 Proton pump inhibitors should be co-prescribed for all patients 
on regular NSAIDs/COX-2 inhibitors irrespective of GI risks. 12 Only 
celecoxib has been shown to reduce mucosal harm throughout 
the entire GI tract. 11 Celecoxib is most likely the optimum choice 
NSAID for patients receiving palliative care, as it has a lower GI 
risk, and a similar CV and renal impairment risk compared to non-
selective NSAIDs. 8 
 The lowest effective dose of all NSAID regimens should be used 
for the shortest duration. Treatment should be regularly reviewed 
and discontinued if no benefit or intolerable side effects develop. 9 
They should be used with caution in high-risk elderly patients 
because of GI, renal and CV toxic effects. 13 
 >  Practice point: If an NSAID is needed in patients with CV risk 
factors, they should be prescribed naproxen (1 g/24 h) or low 
dose ibuprofen (<1200 mg/24 h). In patients at very high risk of 
upper GI complications, NSAIDs should be avoided; for those in 
whom it is essential, celecoxib (200 mg/24 h) plus a proton pump 
inhibitor has been recommended. 
 Opioid analgesics 
 Weak opioids (eg codeine) have traditionally been prescribed 
before strong opioids (eg morphine) for the management for 
cancer pain. Codeine is, however, a prodrug of morphine, being 
metabolised by cytochrome P450 CYP2D6 to its active metabolite, 
morphine. Patients who have inactive copies of CYP2D6 (poor 
metabolisers) may find codeine is ineffective, while those with 
additional copies (ultrarapid metabolisers) are at risk of opioid 
toxicity. 14 Starting a low-dose strong opioid (eg ≤30 mg/day oral 
morphine) has been shown to give better pain relief than using 
weak opioids such as codeine. 9 , 15 For patients being converted 
from a weak to a strong opioid, with normal renal and hepatic 
function, a typical starting dose is 10–15 mg oral sustained-release 
morphine twice daily, plus as required 5 mg oral immediate-
release morphine. 9,16 For opioid naive patients, smaller doses of 
immediate-release morphine as required and/or modified-release 
morphine are generally prescribed, monitored and titrated to 
effect / side effects. 9 
 Choice of opioid 
 European Association of Palliative Care guidance states there 
are no important differences between morphine, oxycodone and 
hydromorphone given by the oral route and suggests that any one 
of these three drugs can be used as the first-choice strong opioid 
for moderate to severe cancer pain. 15 This was also illustrated in a 
Cochrane Review of 17 studies which suggested that oxycodone 
has similar analgesic effects and adverse events to other strong 
opioids and that oxycodone or morphine can be used as first-line 
oral opioids for relief of cancer pain. 17 National Institute for Health 
and Care Excellence (NICE) guidance recommends morphine as 
first line in patients with advanced or progressive disease. 16 
>  Practice point: NICE GC140 recommends that morphine should 
be used as fi rst-line oral opioid for relief of cancer pain. 
 Side effects 
 Opioids have a range of potential side effects (Table  1 ). A recent 
overview of Cochrane Reviews evaluated adverse events after 
 Table 1.  Side effects of therapeutic opioids. 
Reproduced with permission from Boland  et al 33 
System Effects 
Gastrointestinal Constipation, xerostomia, nausea and 
vomiting, gastro-oesophageal reflux
Neurological Delirium, hallucinations, sedation, myoclonus, 
hyperalgesia, seizures, headaches
Cardiovascular Bradycardia, hypotension
Pulmonary Respiratory depression, non-cardiogenic 
pulmonary oedema
Urological Urinary retention, altered renal function
Endocrinological Hypogonadism, sexual dysfunction, 
osteoporosis
Immune T cell, natural killer (NK) cell, neutrophil and 
monocyte dysfunction, cytokine dysregulation 
(clinical effect unknown)
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≥2 weeks opioid use for chronic non-cancer pain in adults. 18 
Fourteen reviews showed a significant increased risk of adverse 
events (including constipation, dizziness, drowsiness, fatigue, hot 
flushes, increased sweating, nausea, pruritus and vomiting) with 
opioids compared to both placebo (risk ratio [RR] 1.42, 95% CI 
1.22–1.66) and non-opioid analgesics (RR 1.21, 95% CI 1.10–1.33). 
There was also a significant increased risk of experiencing a serious 
adverse event with opioids compared to placebo (RR 2.75, 95% CI 
2.06–3.67). 
 The various opioids have slightly different side effect profiles, partly 
due to their varying physicochemical and opioid receptor binding 
affinities. 9 In chronic cancer pain, an RCT evaluating morphine, 
oxycodone, buprenorphine and fentanyl assessed adverse effects 
as a secondary outcome. 19 Differences were observed for reactions 
involving the nervous system (confusion, hallucinations, myoclonus). 
Hallucinations occurred in 13.2% of patients taking morphine, but 
only 6.2% with oxycodone and buprenorphine, and 2.4% with 
fentanyl (p=0.001). Severe myoclonus was not seen with oxycodone 
but occurred in 4.7% of cases with morphine (p=0.029). High 
levels of confusion were less frequent with fentanyl (6.3%) than 
with morphine (15.5%), (p=0.018). Drowsiness, constipation and 
dry mouth occurred in more than half the participants and equally 
among opioids. 19 Other sources associate less constipation with the 
use of transdermal opioids. 20–22 
 Some clinicians and patients are apprehensive about prescribing/
taking opioids as they are concerned that they might affect 
survival via immune and other mechanisms; this potentially leads 
to inadequate pain control. 23 – 28 A systematic review reported that 
in the last days-to-weeks of life opioids did not influence survival, 
but there was a possible association between longer-term opioid 
use and shorter survival in adult patients with cancer. 27 The studies 
that met the criteria for inclusion were mostly poor quality and 
the effect of opioids on survival was not the primary outcome, so 
causality cannot be established. 27 Furthermore, the relationship 
between opioid use and shorter survival may be due to more 
aggressive disease being more painful, necessitating opioid use; the 
primary association might be between the more aggressive disease 
and shorter survival. 29,30 Pain might also affect survival, so based 
on currently available data opioids should continue to be used. 31,32 
 Opioid prescribing considerations 
 Morphine is generally avoided or used with extreme caution in 
patients with moderate to severe renal or hepatic disease, and 
specialist advice should be sought before prescribing strong 
opioids in these patients. 16 In addition, the Faculty of Pain 
Medicine suggests that once a patient is on 120 mg/day oral 
morphine or equivalent, specialist advice should be sought as 
the risk of harm substantially increases beyond this dose. 34 Side 
effects such as nausea, constipation and drowsiness and signs of 
toxicity should be discussed with patients when starting any opioid 
and patient preference considered. 16 
>  Practice point: Once a patient is on 120 mg/day oral morphine 
or equivalent, specialist advice should be sought. Seek specialist 
advice in patients with renal or hepatic disease. 
 Transdermal opioids 
 Buprenorphine and fentanyl are very potent strong opioids, 
often used as transdermal patches (Table  2 ). They can be used 
when oral opioids are not tolerated, when patients are unable 
to swallow or when there are compliance issues. In most cases 
patients also take an oral immediate release preparation of 
morphine or oxycodone as a rescue dose for breakthrough pain. 20 
National Institute for Health and Care Excellence guidelines do not 
recommend transdermal opioids as a first-line treatment when oral 
opioids are appropriate. 16 Inability to rapidly titrate dosages makes 
these patches unsuitable for use in severe uncontrolled pain. 16 
 Effective systemic analgesic concentrations of transdermal 
fentanyl are generally reached within 3 to 23 hours, with steady 
state plasma concentrations achieved within 36 to 48 hours. 9 After 
48 hours, if patients are requiring two or more rescue doses/day to 
effectively treat breakthrough pain, they should be assessed for a 
dose increase (by 12–25 mcg/h). 9 
 Effective systemic analgesic concentrations of transdermal 
buprenorphine are generally reached within 11 to 24 hours, 
with steady state being reached after 1 to 3 days (depending 
on preparation). 9 After 72 hours, if patients are requiring two or 
more rescue doses/day to effectively treat breakthrough pain, 
they should be assessed for a dose increase to the next available 
strength. 9 
 Buprenorphine and fentanyl are both associated with less 
constipation than equianalgesic doses of slow-release morphine 
and buprenorphine has been shown to cause less cognitive 
dysfunction than other opioids. 20–22 
>  Practice point : Buprenorphine and fentanyl are both 
associated with less constipation than equianalgesic doses 
of slow-release morphine. The lowest patch strength of 
buprenorphine (5 mcg/h) is suitable for opioid naive patients; 
the lowest patch strength of fentanyl (12 mcg/h) is not suitable 
for opioid-naive patients. 








Codeine PO 0.1 Codeine 240 mg PO 
= morphine 24 mg PO
Tramadol PO 0.1–0.2 Tramadol 400 mg/24 h PO 




1.5–2 Morphine 60 mg/24 h PO 




70–115 Morphine 40–60 mg/24 h PO 
= buprenorphine 600 mcg/24 
h = 25 mcg/h patch
Fentanyl TD 100–150 Morphine 60–90 mg/24 h PO 
= fentanyl 600 
mcg/24 h = 25 mcg/h patch
Morphine SC 2 Morphine 60 mg/24 h PO 
= morphine 30 mg/24 h SC
 aModified with permission from the Palliative Care Formulary 6th edition, 
palliativedrugs.com Ltd, Nottingham, UK. Some conversions are not agreed 
upon and expert opinion/local practice thus varies. PO = oral; TD = transdermal; 
SC = subcutaneous 
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 Opioid-induced hyperalgesia 
 Patients can paradoxically show an increased sensitivity to 
painful stimuli with increasing doses of opioids. This is termed 
opioid-induced hyperalgesia (OIH). Pain may be experienced 
in a different location and be of a different quality than the 
original pain. It generally occurs with high or rapidly increasing 
doses. 35 If OIH is suspected, a specialist should be contacted for 
advice. Management of OIH can involve changing the opioid, a 
reduction in the dose (by 25 to 50%) and addition of non-opioid 
analgesics. 9,35 
 Opioid switching 
 There is varying efficacy and tolerability to different opioids. 
Thirty percent of patients on morphine fail to achieve satisfactory 
analgesia (despite escalating doses) or experience intolerable 
side effects. 36 Opioid switching has been shown to be effective 
in more than 80% of cancer patients with a poor response to 
an initial opioid. 37 Patients who are stable on an opioid for a 
significant period of time may require increasing doses due to 
disease progression and/or tolerance. Drug tolerance may develop 
to both the analgesic and the central effects (eg drowsiness) of 
the drug, while tolerance to the peripheral side effects of the drug 
(eg constipation) is less common. Incomplete ‘cross-tolerance’ 
may allow the use of lower doses of alternative opioids permitting 
adequate analgesia without significant side effects. 38 Switching 
is not only used for OIH but also intolerable side effects, patients 
who develop renal failure and patients with poor adherence to 
certain opioids. 
 An RCT compared the clinical analgesic response to oral 
morphine vs oral oxycodone as first-line treatment for cancer-
related pain. 36 In the study, non-responders to the first opioid were 
switched to the alternative opioid, and their analgesic response 
was also evaluated. Sixty-two percent of patients randomised 
to morphine as the initial opioid had a good clinical response 
vs 67% who were randomised to oxycodone. There was no 
significant difference in clinical response rates to first-line opioid 
(p=0.48). Patients who did not respond to the first-line opioid were 
switched. Fifty-two percent of patients switched from morphine 
to oxycodone responded. Sixty-seven percent of patients switched 
from oxycodone to morphine responded. There was no difference 
in overall response rates depending on which drug was used first 
(p=0.81). This study shows that opioid switching can be used 
effectively in patients who do not respond to a first-line opioid. 
 When switching between different opioids, the dose of the new 
opioid should be reduced by about 25% (consult local guidance 
and/or specialist advice) to account for incomplete cross-tolerance. 35 
 Using equianalgesic tables 
 Opioid conversion ratios are a guide only. See Table  2 for some 
common conversion ratios; more detailed tables can be found 
elsewhere (eg PCF6 9 and the Palliative Care Adult Network 
guidelines 39 ). Consult local guidance and/or specialist advice when 
changing patients’ opioids. 
 Equianalgesic doses may differ due to interpatient variability 
secondary to drug pharmacokinetics, drug interactions, genetic 
differences and comorbidities, as well as drug manufacturer. 9 
Careful monitoring is needed during conversion to prevent under 
dosing or excessive dosing. 
 Tapentadol 
 A recent alternative to traditional strong opioids is tapentadol; 
licensed for both moderate to severe acute pain requiring opioids 
and severe chronic pain including cancer pain. Tapentadol is a 
weak μ-opioid receptor agonist (18 times less potent binding 
affinity than morphine) and a noradrenaline reuptake inhibitor. 40 
The two distinct pharmacological actions are thought to 
synergistically enhance the descending inhibitory pain pathway. 41 
 A Cochrane review of oral tapentadol in patients with cancer 
pain, included four studies (<200 patients per treatment arm) 
comparing prolonged-release tapentadol with modified-release 
morphine or oxycodone; meta-analysis was not possible. 42 The 
review concluded that tapentadol was neither superior nor inferior 
to oxycodone or morphine. 
 Although tapentadol is a weak opioid, its side-effect profile 
is similar to strong opioids. Recent reviews report decreased 
GI-related side effects (nausea, vomiting and constipation) with 
tapentadol used for both cancer and chronic pain, when compared 
to strong opioids. 40,43,44 Dry mouth and headache were reported 
more often than with oxycodone or placebo. 44 
>  Practice point: Tapentadol prolonged-release should be 
considered an alternative for patients in whom traditional strong 
opioids have failed to provide adequate pain control, especially 
when doses are limited by intolerable side effects. 
 Coanalgesics 
 Coanalgesic (or adjuvant) medications refer to drugs which 
were originally marketed for indications other than pain. These 
include antidepressants such as amitriptyline and duloxetine, and 
anti-epileptics such as gabapentin and pregabalin. The number 
of these drugs has increased substantially over the last decade. 
Duloxetine is a serotonin–noradrenaline reuptake inhibitor that is 
licensed for treatment of diabetic peripheral neuropathic pain. In a 
multicentre randomised crossover trial of duloxetine vs placebo, 45 it 
significantly reduced the average pain score in patients with painful 
chemotherapy-induced peripheral neuropathy from platinum and 
taxane agents. The duloxetine-first arm reported a mean decrease 
in average pain of 1.06 (95% CI 0.72–1.40) vs 0.34 (95% CI 0.01–
0.66) among those who received placebo (p=0.003). The observed 
mean difference in average pain score between the duloxetine-first 
and placebo-first groups was 0.73 (95% CI 0.26–1.20). Duloxetine 
also improved quality of life scores and decreased numbness and 
tingling. Although an intention-to-treat analysis was done, the 
dropout rate due to adverse events in the duloxetine first group was 
11% vs 1% in the placebo group (p<0.001). 45 
 National Institute for Health and Care Excellence guidance 
recognises that many of the treatments used to treat neuropathic 
pain are unlicensed and this limits their use outside of specialist 
settings. 46 The guidance suggests using one of amitriptyline, 
duloxetine, gabapentin or pregabalin as initial treatment for 
neuropathic pain (except trigeminal neuralgia). If initial treatment 
is not effective or not tolerated, it is advisable to change to a 
different class of drug and change again if second and third drugs 
are not effective. Combination therapy may also be a helpful 
option if the initial choices do not sufficiently improve pain. 46 
 A double-blind RCT assessed the clinical efficacy of pregabalin, 
amitriptyline and gabapentin in neuropathic cancer pain compared 
to placebo. 47 All three drugs were effective in relieving cancer-
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related neuropathic pain, with statistically and clinically significant 
morphine sparing effect of pregabalin in relieving neuropathic 
cancer pain and neuropathic symptoms compared to the other 
antineuropathic medications. 47 However, a systematic review 
(which included the above study as the only RCT) appraised the 
literature of pregabalin in the treatment of neuropathic pain 
resulting from cancer or cancer treatment and found there were 
limited published data reporting efficacy and safety outcomes 
for pregabalin in the treatment of neuropathic pain in adults with 
cancer. 48 Due to limitations within the studies included in the 
review, the authors felt it was not possible to draw any conclusions 
on pregabalin for the treatment of cancer-related neuropathic pain. 
 A meta-analysis of four RCTs examined whether combining 
opioids with pregabalin or gabapentin, compared to opioid 
monotherapy improved cancer pain. 49 There was no significant 
difference in pain relief between groups; however, adverse 
events were more frequent in the combination arms. Due to 
heterogeneity and the relative poor quality of RCTs, the benefit 
of combination therapy in patients with neuropathic cancer pain 
cannot be discounted and therefore clinicians should balance 
potential benefits against the recognised adverse effects of 
combination therapy. 49 
 European Association of Palliative Care guidance recommends 
that amitriptyline or gabapentin should be considered for patients 
with neuropathic cancer pain that is only partially responsive to 
opioid analgesia. 15 The combination of an opioid with these drugs 
is more likely to cause adverse central nervous symptoms and so 
careful dose titration and review should occur.
>  Practice point: Gabapentin, pregabalin, amitriptyline or 
duloxetine should be considered for patients with neuropathic 
cancer pain that is only partially responsive to opioid analgesia. 
Adverse central nervous symptoms are common with 
coanalgesic drugs and clinicians should balance any potential 
benefi ts against recognised adverse effects of combining 
opioids with coanalgesics. 
 Conclusion 
 There are some recent developments in the pharmacological 
management of pain in palliative care. There are, however, key 
gaps in the evidence and further research studies in all drug 
classes are needed. Patients’ treatment must be individualised, 
weighing up the risks and benefits of medication, while considering 
patient comorbidities. A reassessment of response (beneficial and 
adverse effects) to medications must be undertaken frequently 
and drugs should be stopped if there is no sign of clinical 
improvement or unmanageable adverse effects. Specialist advice 
should be sought if unsure. ■ 
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